Abeona Therapeutics (ABEO) Projected to Post Earnings on Tuesday

Abeona Therapeutics (NASDAQ:ABEO) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $5.6470 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 8:30 AM ET.

Abeona Therapeutics Trading Up 6.4%

Shares of ABEO stock opened at $5.16 on Tuesday. The company has a market capitalization of $279.62 million, a PE ratio of 4.20 and a beta of 1.13. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.54. The business’s fifty day moving average is $5.15 and its 200 day moving average is $5.32. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ABEO shares. Wall Street Zen cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a report on Monday. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Insider Buying and Selling

In other Abeona Therapeutics news, Director Leila Alland sold 18,065 shares of Abeona Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total transaction of $91,950.85. Following the completion of the sale, the director owned 173,614 shares of the company’s stock, valued at $883,695.26. The trade was a 9.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Eric Crombez sold 16,284 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $5.09, for a total value of $82,885.56. Following the completion of the transaction, the director owned 63,456 shares of the company’s stock, valued at $322,991.04. The trade was a 20.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 209,605 shares of company stock valued at $1,101,300 in the last three months. 5.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abeona Therapeutics

A number of large investors have recently modified their holdings of ABEO. Legal & General Group Plc purchased a new stake in Abeona Therapeutics in the second quarter worth approximately $27,000. Russell Investments Group Ltd. bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth approximately $37,000. Truvestments Capital LLC boosted its stake in shares of Abeona Therapeutics by 191.4% in the 4th quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 6,770 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of Abeona Therapeutics in the 3rd quarter valued at $64,000. Finally, Man Group plc bought a new position in shares of Abeona Therapeutics during the 2nd quarter valued at $67,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.